POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING GLYPICAN-3 AND T CELL RECEPTOR

TREATMENT OF ANTI-PLA2R AUTOANTIBODY-MEDIATED MEMBRANOUS NEPHROPATHY

OFATUMUMAB FOR TREATING PEDIATRIC MS

METHODS OF TREATING MULTIPLE MYELOMA

Application of a nanobody targeting on IL-6RA

COMBINATION THERAPY AND RELATED METHODS

COMPOSITIONS, DOSES, AND METHODS FOR TREATMENT OF THYROID EYE DISEASE

MULTISPECIFIC ANTIBODIES FOR IMMUNO-ONCOLOGY

B7-H3 ANTIBODY AND USE THEREOF

ANTIBODY MOLECULES TO PG-L1 AND METHODS OF TREATING CANCER AND INFECTIOUS DISEASES

PHARMACEUTICAL COMPOSITION FOR TREATING SMALL CELL LUNG CANCER

ANTI-CTLA4 ANTIBODIES AND USES THEREOF

USE OF AN ANTI-TGFßR2/PD-1 BISPECIFIC ANTIBODY

ASSESSING AND TREATING MESOTHELIOMA

CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS

COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCERS BY TARGETING IGSF8

ANTI- GPRC5D ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND GPRC5D AND CD3, AND USES THEREOF

ANTIBODY FORMULATIONS

ANTIBODY TO CXCL12 AND COMPOSITION COMPRISING SAME FOR TREATMENT OF HAIR LOSS

BISPECIFIC FUSION POLYPEPTIDE AND APPLICATION THEREOF

SCFV-FC DIMERS THAT BIND TRANSFORMING GROWTH FACTOR-BETA1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY

NOVEL BIFUNCTIONAL MULTISPECIFIC ANTAGONISTS CAPABLE OF INHIBITING MULTIPLE LIGANDS OF TGF-BETA FAMILY AND USES THEREOF

METHODS FOR TREATING SICKLE CELL DISEASE OR BETA THALASSEMIA USING A COMPLEMENT ALTERNATIVE PATHWAY INHIBITOR

TREATMENT OF MEDICATION OVERUSE HEADACHE USING ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES

Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity

CONSTRUCTS HAVING A SIRP-ALPHA DOMAIN OR VARIANT THEREOF

PROTEASE-MEDIATED TARGET SPECIFIC CYTOKINE DELIVERY USING FUSION POLYPEPTIDE

STEM CELL-NANO DRUG DELIVERY SYSTEM COMPLEX, USE THEREOF AND METHOD FOR PREPARING THE SAME

Glycan-Interacting Compounds and Methods of Use

ANTIBODIES SPECIFICALLY BINDING TO MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS

AUTOIMMUNE ANTIBODIES FOR USE IN INHIBITING CANCER CELL GROWTH

TISSUE-DIRECTED ANTIBODIES AND METHODS OF USING THE SAME

ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES

PHARMACEUTICAL COMBINATION AND APPLICATION THEREOF

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING TUMOR, AND USE THEREOF

ANTI-PD-1 ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF

COMPOSITIONS AND METHODS FOR TREATING MELANOMA

COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF TMIGD2

CONDITIONAL ACTIVATION OF IMMUNOGLOBULIN MOLECULES

BISPECIFIC ANTIBODIES AND USES THEREOF

ENTPD2 ANTIBODIES, COMBINATION THERAPIES, AND METHODS OF USING THE ANTIBODIES AND COMBINATION THERAPIES

ANTIGEN-BINDING POLYPEPTIDES DIRECTED AGAINST CD38

HOMOLOGOUS DIMERIZATION PEPTIDES AND ANTIBODIES COMPRISING THE SAME

ANTIBODIES TO CD40

BIOMARKERS FOR CD40 AGONIST THERAPY

NOVEL MULTI-SPECIFIC MOLECULES

ANTIBODIES SPECIFIC TO SIALIC ACID-BINDING IG-LIKE LECTIN 15 AND USES THEREOF

ANTI-CD47 ANTIBODIES AND USE THEREOF

MONOCLONAL ANTIBODIES TO PROTECT AGAINST GRAM-NEGATIVE PATHOGENS

HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF

OSTRICH ANTIBODY FOR BACTERIAL INFECTIOUS DISEASES

MULTISPECIFIC BINDING AGENTS AGAINST CD40 AND CD137 IN COMBINATION THERAPY FOR CANCER

METHODS OF EFFECTING A HEMODYNAMIC CHANGE BY ADMINISTERING AN ANTI-NPR1 ANTIBODY

COMPOSITIONS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND METHODS FOR MAKING AND USING THE SAME

BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLS

METHOD FOR TREATING MULTIPLE SCLEROSIS

ANTI-BCMA ANTIBODY-DRUG CONJUGATES AND METHODS OF USE

B CELL MATURATION ANTIGEN BINDING PROTEINS

ENGINEERED IMMUNE CELLS TARGETING BCMA AND THEIR USES THEREOF

STEROID SPARING

TIE2-BINDING AGENTS AND METHODS OF USE

ACTIVATABLE ANTIBODIES AND METHODS OF USE THEREOF

DUAL RECEPTOR ANTAGONISTIC ANTIGEN-BINDING PROTEINS AND USES THEREOF

Cation-Independent Mannose-6-Phosphate Receptor Binders For Targeted Protein Degradation

HIF-1a INHIBITOR

METHODS AND COMPOSITIONS FOR TREATING CANCER

ANTI-PD-L1 NANOBODY AND USE THEREOF

Multivalent and bispecific antibody constructs and methods of use thereof

COMPOSITIONS AND METHODS FOR TREATMENT OF RETINAL DEGENERATION

A33 ANTIBODY COMPOSITIONS AND METHODS OF USING THE SAME IN RADIOIMMUNOTHERAPY

DRUG FOR PREVENTING, ALLEVIATING OR TREATING MUCOSAL ADHESION AND USE THEREOF

Fc VARIANTS WITH ALTERED BINDING TO FcRn

METHODS AND COMPOSITIONS FOR INCREASING IDURONATE 2-SULFATE ACTIVITY IN THE CNS

ANTIBODIES TO CORONAVIRUS SARS-COV-2

ANTI-HBV ANTIBODIES AND USES THEREOF

BUTYROPHILIN-LIKE 2 AGENTS FOR TREATING INFLAMMATORY DISORDERS

FUSION PROTEINS COMPRISING SUPPRESSION OF TUMORIGENICITY 2 OR INTERLEUKIN-33, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS

LABELING OF ANTIBODIES

PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS

METHODS FOR TREATING CANCER

TREATMENT WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH CTLA-4 AND PD-1 INHIBITORS

USE OF COMBINATION THERAPY FOR TREATING CANCER

CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS

METHODS FOR DETECTING AND INHIBITING BRAIN METASTASIS

MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES

ANTI-DCLK1 ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS, AND COMPOSITIONS AND METHODS OF USE THEREOF

PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTION AND/OR TREATMENT OF DISEASE THAT DEVELOPS OR PROGRESSES AS A RESULT OF DECREASE OR LOSS OF ACTIVITY OF BLOOD COAGULATION FACTOR VIII AND/OR ACTIVATED BLOOD COAGULATION FACTOR VIII

HER2 SINGLE DOMAIN ANTIBODIES VARIANTS AND CARS THEREOF

Binding agents targeting TROP2-expressing tumor cells

BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLS

ANTI-TAX INTERACTING PROTEIN-1 (TIP1) BINDING MOLECULES

METHOD FOR ALLOWING IMMUNE CELLS INFILTRATION IN TUMORS

VARIANTS OF CD38 ANTIBODY AND USES THEREOF

Epithelial Cadherin-Specific Antibodies

REGIMENS AND METHODS OF TREATING MULTIPLE SCLEROSIS USING OFATUMUMAB

ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODY HAVING IMPROVED BLOOD-BRAIN-BARRIER PERMEABILITY, AND MULTI-SPECIFIC ANTIBODY AND PHARMACEUTICAL COMPOSITION WHICH USE SAME

USE OF ANTI-CD40 ANTIBODIES FOR TREATMENT OF INFLAMMATORY CONDITIONS

ANTI-OX40 MONOCLONAL ANTIBODY AND METHODS OF USE THEREOF

ANTI-HVEM ANTIBODIES

POLYPEPTIDE COMPLEXES WITH IMPROVED STABILITY AND EXPRESSION

HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATION

Use of Anti-EGFR/Anti-Met Antibody to Treat Gastric or Esophageal Cancer

B7-H4 ANTIBODY DOSING REGIMENS

ANTI-PD-L1 ANTIBODY AND USE THEREOF

CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF

METHODS FOR TREATING CANCER WITH ANTI-ILT3 ANTIBODIES

NOVEL DARPIN BASED CD33 ENGAGERS

INHIBITORS OF IL-11 OR IL-11Ra FOR USE IN THE TREATMENT OF ABNORMAL UTERINE BLEEDING

METHODS FOR TREATING CORONAVIRUS INFECTION AND RESULTING INFLAMMATION-INDUCED LUNG INJURY

ANTIBODY AGAINST INHIBIN AND USE THEREOF

ANTI-SURVIVIN ANTIBODIES FOR TREATMENT OF AUTOIMMUNE DISEASES

MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS

ANTIBODIES AGAINST INFLUENZA A VIRUSES

HEPATITIS B ANTIBODIES

NK CELL ENGAGER MOLECULES AND METHODS OF USE

PEPTIDES FOR IMMUNOTHERAPY

Human Antibodies To PD-1

HUMAN IPSC-DERIVED MACROPHAGE

METHOD OF RECONSTITUTING LYOPHILIZED FORMULATION

VACCINE COMPOSITIONS AND METHODS OF USING THE SAME

METHODS OF TREATING CANCER USING RECOMBINANT MICROORGANISMS EXPRESSING A STING AGONIST

IMMUNE CELLS ENGINEERED TO PROMOTE THANOTRANSMISSION AND USES THEREOF

ERK1/2 INHIBITOR COMBINATION THERAPY

ANTIBODIES AGAINST ROR1 AND USES THEREOF

NOVEL MULTISPECIFIC ANTIBODIES

BIFUNCTIONAL DEGRADERS OF GALACTOSE-DEFICIENT IMMUNOGLOBULINS

NOVEL ANTI-PAD4 ANTIBODY

METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES

ANTI-CD40 ANTIBODIES FOR USE IN TREATING AUTOIMMUNE DISEASE

COMPOSITIONS COMPRISING HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF

ANTI-CD25 ANTIBODY AGENTS

Anti-Trkb Monoclonal Antibodies And Methods Of Use

HUMANIZED ANTI-CLEC-1A ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF AND MIMETICS THEREOF

ANTIGEN BINDING PROTEIN AND USE THEREOF

ANTIBODIES BINDING TO CSF1R AND CD3

HUMAN ANTI-SEMAPHORIN 4D ANTIBODY

MODULATION OF ANDROGEN SIGNALING TO INNATE IMMUNE KILLING OF PROSTATE CANCER

ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE

ANTI-CD112R ANTIBODY AND USE THEREOF

PHARMACEUTICAL COMPOSITION CONTAINING ANTI-TSLP ANTIBODY

COMBINATION TREATMENT OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN PATIENTS WITH RAS PATHWAY MUTATIONS

ANTI-APOE ANTIBODIES

TAU-SPECIFIC ANTIBODY GENE THERAPY COMPOSITIONS, METHODS AND USES THEREOF

MODULATION OF ANTIBODY FUNCTION VIA SIALIC ACID MODIFICATION

COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES

IL-2 MUTEINS FOR TREATING CANCER OR INFECTION

ENHANCED TARGETING USING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES

Methods and Compositions for Treating Cancer

METHODS OF TREATING CANCER USING TIGIT INHIBITORS AND ANTI-CANCER AGENTS

Synergistic Inhibition of eIF5A and Notch Signaling in Intermediate Tregs

COMPOSITIONS AND METHODS OF TREATING SARCOMA LUNG METASTASIS

COMBINATIONS OF AN ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY, A PLATINUM-BASED ANTINEOPLASTIC DRUG, AND A TAXANE

COMBINATION THERAPY FOR CANCER

ADIPONECTIN ALONE OR IN COMBINATION WITH EXTRACORPOREAL PHOTOPHERESIS (ECP) FOR IMMUNE RELATED ADVERSE EVENTS OF IMMUNE CHECKPOINT INHIBITORS

Pharmaceutical Composition for Preventing or Treating Systemic Sclerosis

METHODS AND MATERIALS FOR TREATING CANCER

ONCOLYTIC VIRUS STRAIN

CHIMERIC ANTIGEN RECEPTOR

ANTI-STEAP1 ANTIGEN-BINDING PROTEIN

TUMOR-ASSOCIATED ANTIGENS AND CD3-BINDING PROTEINS, RELATED COMPOSITIONS, AND METHODS

HUMANIZED GPC3 ANTIBODY AND APPLICATION THEREOF

HIGH AFFINITY MONOCLONAL ANTIBODIES TARGETING GLYPICAN-2 AND USES THEREOF

METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF T CELL REDIRECTING THERAPEUTICS

ANTI-CD73 COMPOUNDS TO TREAT ONCOVIRUS-POSITIVE CANCERS

ANTIGEN BINDING MOLECULES WITH INCREASED FC RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION

BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA

ANTI-OX40 ANTIBODY AND USES THEREOF

ANTI-CXCR2 ANTIBODIES AND USES THEREOF

ANTIBODY MOLECULES

USE OF ANTI-IL-36R ANTIBODIES FOR THE TREATMENT OF HIDRADENTITIS SUPPURATIVA (HS)

LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb1 AND USES THEREOF

IMPROVING ANTIBODY TOLERABILITY ASSOCIATED WITH INTRAVENOUS ADMINISTRATION

Anti-PD-L1 Antibody and Usethereof

ANTIBODY SPECIFICALLY BINDING WITH PD-L1 AND ANTIGEN-BINDING FRAGMENT OF ANTIBODY

PD-1 ANTIBODIES, POLYPEPTIDES AND USES THEREOF

BISPECIFIC ANTIBODY AND USE THEREOF

ANTI-CD3 MULTISPECIFIC ANTIBODIES AND METHODS OF USE

ANTI-CLDN6 AND ANTI-CD3 MULTISPECIFIC ANTIBODIES AND METHODS OF USE

ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF

METHODS OF TREATING CANCER WITH ANTI-TIM-3 ANTIBODIES

CYTOTOXIC ANTI-LAG-3 MONOCLONAL ANTIBODY AND ITS USE IN THE TREATMENT OR PREVENTION OF ORGAN TRANSPLANT REJECTION AND AUTOIMMUNE DISEASE

TIM-3 INHIBITORS AND USES THEREOF

COMBINATION THERAPIES WITH VENETOCLAX AND TIM-3 INHIBITORS

Anti-SLC34A2 monoclonal antibodies and uses thereof

ANTI-CLDN6 ANTIBODIES AND METHODS OF USE

NOVEL BINDING MOLECULE AND USE THEREOF

NEUTRALIZING ANTIBODIES TO IL-17A, FUSION PROTEINS THEREOF, AND USES THEREOF

ANTI-AMYLOID BETA PROTOFIBRIL/OLIGOMER ANTIBODIES AND USES THEREOF

APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF

SELECTIVE TARGETING OF OLIGOMERIC B-AMYLOID

ANTI-STAPHYLOCOCCUS ANTIBODIES AND USES THEREOF

ANTI-HERV-W ENVELOPE PROTEIN ANTIBODY FOR USE IN THE TREATMENT OF PSYCHOTIC DISEASES

ANTIBODIES TO SARS-COV-2

CHIMERIC ANTI-CORONAVIRUS SPIKE PROTEIN ANTIBODIES

TRUNCATED TACI POLYPEPTIDE AND FUSION PROTEIN AND USE THEREOF

COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS

OLIGONUCLEOTIDE CONJUGATES TARGETED TO THE TRANSFERRIN RECEPTOR

ANTI-FOLR1 IMMUNOCONJUGATES AND ANTI-PD-1 ANTIBODY COMBINATIONS

COMBINATION THERAPIES USING AN ANTI-BCMA ANTIBODY DRUG CONJUGATE (ADC) IN COMBINATION WITH A GAMMA SECRETASE INHIBITOR (GSI)

CANCER THERAPIES COMPRISING PEPTIDE LOADED CXCR3- AND CCR5-INDUCING DENDRITIC CELLS AND CHEMOKINE MODULATORY AGENTS

METHOD FOR PRODUCING BLOOD PLASMA PRODUCT USEFUL IN THE TREATMENT OF VIRAL INFECTIONS CHARACTERIZED BY AN UNCONTROLLED RELEASE OF PROINFLAMMATORY CYTOKINES

HUMANIZED ANTI-MUC1* ANTIBODIES AND DIRECT USE OF CLEAVAGE ENZYME

CAR T CELLS THAT TARGET B-CELL ANTIGENS

TARGETING B CELL ACTIVATING FACTOR RECEPTOR (BAFF-R) USING LIGAND-BASED CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELLS

COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF IMMUNOTHERAPIES AND VACCINES

VACCINES BASED ON MUTANT CALR AND JAK2 AND THEIR USES

RECOMBINANT PROTEINACEOUS BINDING MOLECULES

CYTOTOXICITY-INDUCING THERAPEUTIC AGENT

ANTIBODIES TO CHITINASE 3-LIKE-1 AND METHODS OF USE THEREFOR

DOSING REGIMENS OF FACTOR XI/XIA ANTIBODIES

NOVEL ANTITHROMBOTIC ANTIBODY

BCMA Monoclonal Antibody-Drug Conjugate

CHIMERIC ANTIGEN RECEPTORS, COMPOSITIONS, AND METHODS

HUMAN MESOTHELIN CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF

ANTI-SIRPa ANTIBODY

Method and Compositions for Inducing Differentiation of Myeloid Derived Suppressor Cell to Treat Cancer and Infectious Diseases

CEACAM5-dependent 4-1BB-agonistic bispecific antibodies

ANTIGEN BINDING MOLECULES THAT BIND LIGHT

ANTI-NR10 ANTIBODY AND USE THEREOF

IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS

ANTIBODIES

USES OF NK CELL ENGAGING ANTIBODY FUSION CONSTRUCTS FOR TREATMENTS

HETERODIMERIC Fc VARIANTS SELECTIVE FOR Fc GAMMA RIIB

BISPECIFIC FUSION PROTEIN

ANTI-VTCN1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES

ANTI-PD1 ANTIBODIES AND METHODS OF USE

ANTI-CD3 ANTIBODY VARIANT, FUSION PROTEIN, AND APPLICATION

ANTIGEN-BINDING PROTEINS TARGETING CD56 AND METHODS OF PRODUCING THEREOF

UNC5B FUNCTION BLOCKING ANTIBODIES

ANTIGEN-BINDING POLYPEPTIDE BINDING TO CD47, AND USE THEREOF

ANTIBODY SPECIFIC FOR ANTI-BCL-6 ANTIBODY AND METHODS OF USE

NOVEL ANTIGEN BINDING MOLECULE FORMATS

BISPECIFIC ANTIBODIES FOR USE IN TREATMENT OF HIDRADENITIS SUPPURATIVA

Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody

ANTI-ERYTHROPOIETIN ANTIBODY

TGF-BETA INHIBITORS AND THERAPEUTIC USE THEREOF

NOVEL ANTI-GREMLIN1 ANTIBODIES

Modified immunoglobulins for targeting amyloid deposits

Modified immunoglobulins for targeting amyloid deposits

ANTIBODIES TO AMYLOID BETA

ANTI-VENOM ANTIBODIES AND USES THEREOF

SERUM ALBUMIN BINDERS

HUMANIZED ANTIBODIES AGAINST NEISSERIA GONORRHOEAE AND METHODS OF USE THEREOF

COMPOSITION OF PIG POLYCLONAL ANTIBODY FOR ITS USE TO TREAT AND/OR PREVENT ANTIBODY-DEPENDENT MACROPHAGE PRO-INFLAMMATORY CYTOKINE RELEASE IN A PASSIVE ANTI-INFECTIOUS IMMUNOTHERAPY

ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS

INTERLEUKIN-15 BASED IMMUNOCYTOKINES

IL-10 VARIANT MOLECULES AND METHODS FOR TREATING INFLAMMATORY DISEASE AND ONCOLOGY

Respiratory syncytial virus (RSV) vaccine

NUCLEIC ACID CONSTRUCT FOR AIDS GENE THERAPY

Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of use thereof to target dystrophin and to treat Duchenne muscular dystrophy

LSP1-DEFICIENT T CELL

COMPOSITIONS AND METHODS FOR INCREASING THE SERUM HALF-LIFE OF A THERAPEUTIC AGENT TARGETING COMPLEMENT C5

BOVINE COLOSTRUM DERIVED ANTIBODIES AND USES THEREOF

COMBINATION USE OF WT1 ANTIGEN PEPTIDE AND IMMUNOMODULATOR

METHODS FOR DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETES

Methods for Treating and/or Preventing Graft-Versus-Host Disease and/or Diffuse Alveolar Hemorrhage and/or Veno-Occlusive Disease Associated with Hematopoietic Stem Cell Transplant

Bispecific OR-gate chimeric antigen receptor responsive to CD20 and CD19

COMBINATION THERAPIES

USE OF AN RXR AGONIST IN TREATING DRUG RESISTANT HER2+ CANCERS

METHODS AND COMPOSITIONS BASED ON LONGITUDINAL STUDIES

THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER

Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereof

ANTIBODY-NKG2D LIGAND DOMAIN FUSION PROTEIN

BAFF-R ANTIBODIES AND USES THEREOF

INTERLEUKIN 11 RECEPTOR ALPHA SUBUNIT (IL11RA) NEUTRALIZING ANTIBODIES AND USES THEREOF

ALK7 Binding Proteins and Uses Thereof

ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF IN THE TREATMENT OF OCULAR MELANOMA

Targeting Extracellular Matrix Proteins to Regulate NK Cell Function in Peripheral Tissues

TREATMENT OF CANCER USING A HLA-A2/WT1 X CD3 BISPECIFIC ANTIBODY AND A 4-1BB (CD137) AGONIST

BISPECIFIC MOLECULE SPECIFICALLY BINDING TO B7-H3 AND TGFB AND USES THEREOF

ANTI-PDL1 ANTIBODIES AND USES THEREOF

Antibody specifically binding to ICAM-1 and use thereof

BISPECIFIC ANTIBODY

ANTI-PD-1 HUMANIZED ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND APPLICATION THEREOF

BISPECIFIC PD-1 AND TIGIT BINDING PROTEINS AND USES THEREOF

TREATMENT OF EOSINOPHIL OR MAST CELL RELATED DISORDERS

COMPOSITIONS AND METHODS FOR PERMEABILIZING THE BLOOD BRAIN BARRIER

VHH-BASED NKP30 BINDERS

METHODS OF TREATMENT OF AUTOIMMUNE DISORDERS USING ILT7 BINDING PROTEINS

COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DISEASES

HIDE1 COMPOSITIONS AND METHODS

THERAPEUTIC AGENT FOR MUSCULAR ATROPHY

PROTEIN BINDERS TO IRHOM2 EPITOPES

MITIGATING TISSUE DAMAGE AND FIBROSIS VIA LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN (LTBP4)

METHODS FOR TREATING SYSTEMIC SCLEROSIS

METHODS OF USE OF ANTI-IL-2 ANTIBODIES

ANTI-VEGF ANTIBODY AND USE THEREOF

DNA ANTIBODY CONSTRUCTS FOR USE AGAINST PLASMODIUM PARASITES

APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF

ANTIBODIES SPECIFIC TO NELL2 AND METHODS OF USE

ANTI-C1s ANTIBODY

ANTIBODY AGAINST CORONAVIRUS

Intratumoral Alpha-Emitter Radiation in Combination with Vasculature Inhibitors

Intratumoral Alpha-Emitter Radiation in Combination with Immune Checkpoint Regulators

Retinal Disorders

COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS

COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS

COMBINATION OF AN ONCOLYTIC VIRUS, AN ANTI-PD-1 INHIBITOR AND AN ACTIVATOR OF THE INNATE IMMUNE SYSTEM FOR USE IN THE TREATMENT OF PROSTATE CANCER

COMBINATION THERAPY FOR TREATING PIK3CA-MUTATED CANCER

TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS